{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:42:31Z","timestamp":1780494151714,"version":"3.54.1"},"reference-count":83,"publisher":"Elsevier BV","content-domain":{"domain":["clineu-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clineuro.2013.09.016","type":"journal-article","created":{"date-parts":[[2013,12,8]],"date-time":"2013-12-08T14:39:00Z","timestamp":1386513540000},"page":"S21-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents"],"prefix":"10.1016","volume":"115","author":[{"given":"Silvia N.","family":"Tenembaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2013.09.016_bib0005","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/WNL.0b013e3181f4d821","article-title":"Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clineuro.2013.09.016_bib0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/0883073812464816","article-title":"Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network","volume":"28","author":"Julian","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/135245859700300105","article-title":"Multiple sclerosis in childhood: clinical features of 149 cases","volume":"3","author":"Ghezzi","year":"1997","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.59.7.1006","article-title":"Early onset multiple sclerosis: a longitudinal study","volume":"59","author":"Boiko","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458508101933","article-title":"Demographics of pediatric onset multiple sclerosis in an MS center population from the Northeastern United States","volume":"15","author":"Chitnis","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archneurol.2008.505","article-title":"Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1474-4422(10)70249-0","article-title":"Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions","volume":"9","author":"Thompson","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0040","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.41.8.1219","article-title":"Quantitative MRI changes in gadolinium DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis","volume":"41","author":"Barkhof","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1468-1331.2005.01352.x","article-title":"EFNS guidelines on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses","volume":"12","author":"Sellebjerg","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jns.2007.09.025","article-title":"Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing\u2013remitting multiple sclerosis","volume":"267","author":"Zivadinov","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11940-012-0170-0","article-title":"Treatment of acute disseminated encephalomyelitis","volume":"14","author":"Pohl","year":"2012","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ncl.2010.12.012","article-title":"Treatment of multiple sclerosis exacerbations","volume":"29","author":"Repovic","year":"2011","journal-title":"Neurol Clin"},{"issue":"16 Suppl 2","key":"10.1016\/j.clineuro.2013.09.016_bib0065","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1212\/01.wnl.0000259407.40023.ab","article-title":"Treatment of pediatric multiple sclerosis and variants","volume":"68","author":"Pohl","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0070","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/WCO.0b013e3282ff5b8f","article-title":"Use of intravenous immunoglobulin and plasma exchange in neurological disease","volume":"21","author":"Linker","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0075","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0085","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga\u00f1a","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.clineuro.2013.09.016_bib0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2012","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0887-8994(97)80673-X","article-title":"Childhood multiple sclerosis treated with plasmapheresis","volume":"17","author":"Takahashi","year":"1997","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0105","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00115-005-2019-1","article-title":"Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients","volume":"77","author":"Schilling","year":"2006","journal-title":"Nervenarzt"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458511430704","article-title":"Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis","volume":"18","author":"Chitnis","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0120","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1352458510375568","article-title":"The management of multiple sclerosis in children: a European view","volume":"16","author":"Ghezzi","year":"2010","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.clineuro.2013.09.016_bib0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0883073810395141","article-title":"Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists","volume":"26","author":"Waldman","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1212\/01.wnl.0000198257.52512.1a","article-title":"Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis","volume":"66","author":"Banwell","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0135","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/01.WNL.0000153570.33845.6A","article-title":"Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a","volume":"64","author":"Pohl","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/01.wnl.0000231137.24467.aa","article-title":"Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis","volume":"67","author":"Tenembaum","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-2001-17370","article-title":"Interferon beta-1a in children with multiple sclerosis is well tolerated","volume":"32","author":"Waubant","year":"2001","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10072-007-0804-2","article-title":"Treatment of early onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results","volume":"28","author":"Ghezzi","year":"2007","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10072-009-0083-1","article-title":"Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience","volume":"30","author":"Ghezzi","year":"2009","journal-title":"Neurol Sci"},{"issue":"7","key":"10.1016\/j.clineuro.2013.09.016_bib0160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0883073813488828","article-title":"Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study","volume":"28","author":"Tenembaum","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-2003-41274","article-title":"Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis","volume":"34","author":"Kornek","year":"2003","journal-title":"Neuropediatrics"},{"issue":"4","key":"10.1016\/j.clineuro.2013.09.016_bib0170","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archneurol.2010.325","article-title":"Multiple Sclerosis therapies in pediatric patients with refractory multiple sclerosis","volume":"68","author":"Yeh","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0175","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/archneur.65.12.1655","article-title":"Natalizumab use in pediatric multiple sclerosis","volume":"65","author":"Huppke","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejpn.2008.01.007","article-title":"Natalizumab treatment in pediatric multiple sclerosis: a case report","volume":"13","author":"Borriello","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"10.1016\/j.clineuro.2013.09.016_bib0185","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1212\/WNL.0b013e3181f11daf","article-title":"Safety and efficacy of natalizumab in children with multiple sclerosis","volume":"75","author":"Ghezzi","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clineuro.2013.09.016_bib0190","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","article-title":"Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases","volume":"19","author":"Ghezzi","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0195","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1474-4422(08)70020-6","article-title":"Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician","volume":"7","author":"Boster","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0200","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/WNL.0b013e3181a8164c","article-title":"Cyclophosphamide therapy in pediatric multiple sclerosis","volume":"72","author":"Makhani","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0205","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1469-8749.2008.03246.x","article-title":"Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis","volume":"51","author":"Karenfort","year":"2009","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"10.1016\/j.clineuro.2013.09.016_bib0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/01.wnl.0000267662.41734.1f","article-title":"Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results","volume":"69","author":"Rose","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.clineuro.2013.09.016_bib0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2010","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.clineuro.2013.09.016_bib0225","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2011.581","article-title":"Daclizumab use in patients with pediatric multiple sclerosis","volume":"69","author":"Gorman","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0230","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/01.wnl.0000259422.44235.a8","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0235","doi-asserted-by":"crossref","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0255","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","article-title":"Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"77","author":"Scott","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0260","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/787630","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","author":"Bonnan","year":"2012","journal-title":"Mult Scler Int"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0265","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0270","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0275","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.clineuro.2013.09.016_bib0280","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0285","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal multiple sclerosis in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.clineuro.2013.09.016_bib0290","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.clineuro.2013.09.016_bib0295","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.clineuro.2013.09.016_bib0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0305","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does Natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0315","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0320","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0325","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0330","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0335","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clineuro.2013.09.016_bib0340","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0345","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0350","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.clineuro.2013.09.016_bib0355","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","article-title":"Spectrum of pediatric neuromyelitis optica","volume":"122","author":"Lotze","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0360","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0365","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0370","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0883073810381445","article-title":"Efficacy and safety of rituximab in pediatric neuromyelitis optica","volume":"26","author":"Mahmood","year":"2011","journal-title":"J Child Neurol"},{"issue":"6","key":"10.1016\/j.clineuro.2013.09.016_bib0375","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of Rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clineuro.2013.09.016_bib0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.clineuro.2013.09.016_sbref0385a","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jpeds.2012.11.038","article-title":"Leveraging administrative data to monitor Rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States","volume":"162","author":"Kavcic","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.clineuro.2013.09.016_sbref0385b","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.clineuro.2013.09.016_bib0390","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/rheumatology\/kei263","article-title":"Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment","volume":"45","author":"Falcini","year":"2006","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.clineuro.2013.09.016_bib0395","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0400","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.arcped.2007.08.004","article-title":"Devic's neuromyelitis optica in children: a case report and review of the literature","volume":"14","author":"Djemal","year":"2007","journal-title":"Archives de p\u00e9diatrie"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0405","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pediatrneurol.2008.05.016","article-title":"Neuromyelitis optica in a young child with positive serum autoantibody","volume":"39","author":"Loma","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.clineuro.2013.09.016_bib0410","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1590\/S0004-282X2011000100008","article-title":"NMO in pediatric patients: brain involvement and clinical expression","volume":"69","author":"Pe\u00f1a","year":"2011","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846713003703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846713003703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T09:24:52Z","timestamp":1538990692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846713003703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":83,"alternative-id":["S0303846713003703"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2013.09.016","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2013.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}